© All rights reserved to Barnea Jaffa Lande Law offices

Together is empowering

Search by Practice

Insights & News /  IPOs and Public Offerings

September 30, 2016

Barnea & Co. Represented the Private Equity Fund IGP Investment in Jacada

Barnea represented Israel Growth Partners (IGP)  in an agreement to buy 300,000 Jacada shares, 7% of the company's share capital, from Robert (Bob) Ashton's investment firm Kinetic Catalyst Partners.

October 13, 2016

Australian Stock Exchange to Israeli Tech Firms: Come List Down Under

We were interviewed by the Times of Israel about the growing interest of Israeli companies in listing on the Australian Stock Exchange (ASX). We noted that Australia is regarded as having a creative and sophisticated regulatory regime that strikes a good balance between investor protection and a pro-business approach that recognizes the risk of over-regulation.

August 1, 2016

Cellect Biotechnology Completes NASDAQ IPO

In July 2016, Cellect Biotechnology announced that it had completed its NASDAQ IPO, raising USD 8.4 million. Cellect Biotechnology will be traded on NASDAQin parallel with its listing on the Tel Aviv Stock Exchange. Barnea represented a group of US underwriters, led by H.C. Wainwright, LLC, in the process of submitting Cellect Biotechnology's prospectus for the listing. Cellect Biotechnology develops innovative technologies in the stem cells sphere.

    // load AI chatbot on test page